The top five individual shareholders of Johnson and Johnson include CEO, Alex Gorsky—the largest shareholder with 2.9 million shares. Joaquin Duato—J&J’s executive vice president—is the second-largest individual shareholder with 916,576 shares. Paulus Stoffels,
From backing an app that connects Black women to caregivers of color to developing a digital platform that supports surgical recovery, Johnson & Johnson is helping drive the surge of innovation in telemedicine.
While the pandemic hastened the adoption of telehealth, also known as telemedicine, out of necessity, experts predict that virtual and digital healthcare services represent the future of healthcare.
“Think about what else is available virtually or on demand. We can call for a car through apps, we can have groceries delivered to our door, we can watch movies from anywhere,” says Stacy Feld, Head, Johnson & Johnson Innovation, West North America, Australia and New Zealand. “Technology is enabling businesses to be established in this way, and that includes healthcare businesses. Now we just have to focus on better integration of telehealth across the patient journey.”
In October 2010, J&J acquired Crucell for $2.4 billion and will operate as the centre for vaccines, within the wider Johnson & Johnson pharmaceuticals group.
In November 2015, Biosense Webster, Inc. acquired Coherex, Medical Inc. expanding the companies range of treatment options for patients with atrial fibrillation.
In July 2016, J&J announced its intention to acquire the privately held company, Vogue International LLC, boosting Johnson & Johnson Consumer Inc. In September of the same year, J&J announced it would acquire Abbott Medical Optics from Abbott Laboratories for $4.325 billion, adding the new division into Johnson & Johnson Vision Care, Inc.
In January 2017, J&J fought off competition from Sanofi to acquire Swiss drugmaker Actelion. Later in the month J&J announced a $30 billion deal, the largest ever pursued by the company, to purchase the Swiss company Actelion and to spin off its research and development unit, into a separate legal entity. In March, the company declared its tender offer for Swiss biotechnology company Actelion successful on Friday, reporting that Janssen Holding GmbH controlled 77.2 percent of the voting rights after the main offer period, equating to 83,195,346 Actelion shares. In keeping with earlier agreements, the company announced its intention to delist Actelion, while creating the Swiss-based biopharmaceutical company, Idorsia Ltd.J&J will control 16% of Idorsia, with the ability to raise their stake to 32% through convertible notes.
In July 2017, Johnson & Johnson Vision Care
, Inc announced that its Abbott Medical Optics subsidiary would acquire TearScience, who recently received U.S. Food and Drug Administration (FDA) approval for an office-based approach to imaging meibomian glands and treating meibomian gland dysfunction.In September, the company acquired subscription-based contact lens startup Sightbox.
Johnson & Johnson competitors include Bristol Myers Squibb, Merck, Unilever, Pfizer and Procter & Gamble. Johnson & Johnson ranks 1st in Gender Score on Comparably vs its competitors. See below how Johnson & Johnson compares to its competitors with CEO Rankings, Product & Services, NPS, Pricing, Customer Services, Overall Culture Score, eNPS, Gender and Diversity Scores.
Johnson & Johnson is American multinational pharmaceutical and medical equipment, and consumer goods manufacturing company. It was established in the year 1886 and headquartered in New Jersey. It has about 250 subsidiary companies and has its business operations in about 60 countries.
These brands of consumer products are quite popular and are available in almost every household. Their popular consumer products are Band-Aid, Johnson’s baby products, beauty products and many more. It has a very strong presence in each and every product. This brand is trusted by many medical practitioners worldwide. It has a wide range of distribution system for selling their products.
Through this article, let us discuss Johnson & Johnson competitors.
Pfizer is one of the largest pharmaceutical and a research-based company. The company manufactures and produces vaccines and medicines for many disciplines of medicine which includes oncology, cardiology, immunology, diabetology, and neurology.
The company gets help from two business segments, Pfizer Innovative Health and Pfizer Essential Health to manage its commercial operations. Pfizer Innovative Health emphasis on producing medicines and vaccines that target on improving the life of a patient. Pfizer Essential Health is a part of research and development that leads to innovations in the pharmaceutical sector.
The main strength of this brand is that six of their products are among the top pharmaceuticals brands in India. It has an excellent R&D wing that continuously produces and innovate products. Due to the strong brand name, Pfizer is regarded as one of the top Johnson & Johnson competitors.